CG Oncology (CGON) rose over 4% on Monday after the company said roughly 76% of patients in a phase 3 trial of cretostimogene for high-risk bladder cancer showed a complete response at some point.
As of Jan. 20, 46% of patients remained in complete response at 12 months, with 30 confirmed responses at 24 months.
The study evaluated cretostimogene monotherapy for high-risk Bacillus Calmette Guerin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Data show that 83 out of 110 patients in the trial achieved complete response at some point.
Data also showed that cretostimogene levels peaked immediately after administration and lasted locally for 4 to 5 days. There was no systemic exposure reported.
These results were presented at the recent annual European Association of Urology Congress in Madrid, Spain.
Price: 28.26, Change: +1.21, Percent Change: +4.47
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。